BioCentury | Jul 15, 2020
Product Development
INmune therapy shows promise in Alzheimer’s, but cognitive test still to come
After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The...